Literature DB >> 14749121

Mouse models of pancreatic cancer: the fur is finally flying!

Steven D Leach1.   

Abstract

Pancreatic cancer remains one of the most lethal of all human malignancies. Until recently, preclinical studies have been hampered by the absence of mouse models faithfully recapitulating critical elements of the human disease. However, recent months have witnessed a flurry of activity with respect to prospective mouse models. This progress now allows the evaluation of novel strategies for early detection, chemoprevention, and therapy and also provides new insights regarding the potential for differentiated and undifferentiated cell types to act as cells of origin for pancreatic ductal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749121     DOI: 10.1016/s1535-6108(03)00337-4

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  26 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

3.  KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.

Authors:  Chanjuan Shi; Seung-Mo Hong; Phillip Lim; Hirohiko Kamiyama; Mehtab Khan; Robert A Anders; Michael Goggins; Ralph H Hruban; James R Eshleman
Journal:  Mol Cancer Res       Date:  2009-02-10       Impact factor: 5.852

4.  A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.

Authors:  Ken Fujimura; Tracy Wright; Jan Strnadel; Sharmeela Kaushal; Cristina Metildi; Andrew M Lowy; Michael Bouvet; Jonathan A Kelber; Richard L Klemke
Journal:  Cancer Res       Date:  2014-09-26       Impact factor: 12.701

5.  Detection of early-stage pancreatic adenocarcinoma.

Authors:  David V Gold; Michael Goggins; David E Modrak; Guy Newsome; Mengling Liu; Chanjuan Shi; Ralph H Hruban; David M Goldenberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-01       Impact factor: 4.254

6.  Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice.

Authors:  Jing Xu; Florence Gattacceca; Mansoor Amiji
Journal:  Mol Pharm       Date:  2013-04-16       Impact factor: 4.939

7.  Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice.

Authors:  Han Bai; Haonan Li; Wanying Zhang; Kristina A Matkowskyj; Jie Liao; Sanjay K Srivastava; Guang-Yu Yang
Journal:  Carcinogenesis       Date:  2011-08-22       Impact factor: 4.944

8.  Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells.

Authors:  Navdeep Chehl; Galina Chipitsyna; Qiaoke Gong; Charles J Yeo; Hwyda A Arafat
Journal:  HPB (Oxford)       Date:  2009-08       Impact factor: 3.647

9.  Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).

Authors:  Haonan Li; Allison L Yang; Yeon Tae Chung; Wanying Zhang; Jie Liao; Guang-Yu Yang
Journal:  Carcinogenesis       Date:  2013-05-20       Impact factor: 4.944

10.  Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.

Authors:  Peter O Simon; Jonathan E McDunn; Hiroyuki Kashiwagi; Katherine Chang; Peter S Goedegebuure; Richard S Hotchkiss; William G Hawkins
Journal:  Int J Cancer       Date:  2009-08-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.